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Perfluorooctanoate (PFOA) and perfluoro­
octane sulfonate (PFOS) are two members 
of the perfluoroalkyl acid (PFAA) class of 
chemicals, man­made compounds used in 
the manufacture of fluoro  polymers, including 
those used for non  stick cookware and breath­
able, waterproof fabrics. PFOA and PFOS can 
also result from the metabolism of fluori  nated 
telomers, compounds used for food package 
coatings, carpet treatments, and stain­resistant 
fabric treatment. PFOA and PFOS persist in 
the environment (Kato et al. 2011; Tao et al. 
2006); potential sources of exposure to PFOA 
and PFOS in humans include drinking water, 
dust, breast milk, food packaging, ambient 
air, and occupation (D’Hollander et al. 2010; 
Goosey and Harrad 2011; Kim et al. 2011; 
Lau et al. 2007).
In rodents and non  human primates, both 
PFOA and PFOS have been found in relatively 
high concentrations in the liver and have been 
associated with liver enlargement. In rats, these 
compounds have been also associated with 
hepatocellular adenomas (Lau et al. 2007). In 
mice, one of the biological effects of PFAAs is 
the activation of the peroxisome proliferator­ 
activated receptor­α (PPAR­α), a ligand­
  activated transcription factor that regulates gene 
expression, lipid modulation, glucose homeo­
stasis, cell proliferation, and inflammation 
(Pyper et al. 2010). Although some effects in 
experimental studies are mediated by PPAR­α 
binding, some other effects occur indepen­
dently of this receptor (Bjork et al. 2011; Ren 
et al. 2009). PPAR­α is also induced by PFOA 
and PFOS in transiently transfected human 
fibroblast­like cell line COS­1, in a concentra­
tion­dependent and in a roughly chain­length–
dependent fashion (Wolf et al. 2008).
Studies in humans have reported incon­
sistent associations between PFOA or PFOS 
and liver enzymes. Transaminase levels have 
been positively associated with PFOA con­
centrations in some occupational studies 
(Costa et al. 2009; Olsen and Zobel 2007; 
Sakr et al. 2007b) but not in others (Costa 
et al. 2009; Sakr et al. 2007b). Similarly, 
γ­glutamyltransferase (GGT) levels have been 
inconsistently associated with PFOA concen­
trations in occupational studies (Costa et al. 
2009; Olsen and Zobel 2007; Sakr et al. 
2007a, 2007b). In a large population­based 
survey, PFOA but not PFOS was associated 
with both transaminase and GGT levels (Lin 
et al. 2010), although those findings differed 
from those of an earlier, much smaller popula­
tion­based study of subjects heavily exposed to 
PFOA (Emmett et al. 2006). Direct bilirubin 
has been found to be negatively associated with 
PFOA concentrations in a few occupational 
studies (Costa et al. 2009; Olsen and Zobel 
2007; Sakr et al. 2007b) but not in others 
(Costa et al. 2009; Sakr et al. 2007a). No asso­
ciation between direct bilirubin and PFOA or 
PFOS was observed in population­based stud­
ies (Emmett et al. 2006; Lin et al. 2010).
From 1950 through 2005, a chemical plant 
in the Mid­Ohio Valley, West Virginia (USA), 
was responsible for emitting PFOA into the 
surrounding environment. In 2001, a group 
of residents filed a class action lawsuit alleging 
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Ba c k g r o u n d: Perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) persist in the 
environment and are found in relatively high concentrations in animal livers. Studies in humans 
have reported inconsistent associations between PFOA and liver enzymes.
oBjectives: We examined the cross-sectional association between serum PFOA and PFOS concen-
trations with markers of liver function in adults.
Me t h o d s : The C8 Health Project collected data on 69,030 persons; of these, a total of 47,092 
adults were included in the present analysis. Linear regression models were fitted for natural log 
(ln)-transformed values of alanine transaminase (ALT), γ-glutamyltransferase (GGT), and direct 
bilirubin on PFOA, PFOS, and potential confounders. Logistic regression models were fitted 
comparing deciles of PFOA or PFOS in relation to high biomarker levels. A multilevel analysis 
comparing the evidence for association of PFOA with liver function at the individual level within 
water districts to that at the population level between water districts was also performed.
re s u l t s: ln-PFOA and ln-PFOS were associated with ln-ALT in linear regression models [PFOA: 
coefficient, 0.022; 95% confidence interval (CI): 0.018, 0.025; PFOS: coefficient, 0.020; 95% CI: 
0.014, 0.026] and with raised ALT in logistic regression models [with a steady increase in the odds 
ratio (OR) estimates across deciles of PFOA and PFOS; PFOA: OR = 1.10; 95% CI: 1.07, 1.13; 
PFOS: OR = 1.13; 95% CI: 1.07, 1.18]. There was less consistent evidence of an association of 
PFOA and GGT or bilirubin. The relationship with bilirubin appears to rise at low levels of PFOA 
and to fall again at higher levels.
co n c l u s i o n s: These results show a positive association between PFOA and PFOS concentrations 
and serum ALT level, a marker of hepatocellular damage.
key w o r d s : C8, cross-sectional study, liver function biomarkers, PFOA, PFOS, population-based 
survey. Environ Health Perspect 120:655–660 (2012).  http://dx.doi.org/10.1289/ehp.1104436 
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health damage from the drinking water sup­
plies drawing on PFOA­contaminated ground­
water (Frisbee et al. 2009). Part of the pre  trial 
settlement of the class action lawsuit included 
a baseline survey, the C8 Health Project, con­
ducted in 2005–2006, that gathered data from 
> 69,000 persons from six contaminated water 
districts surrounding the plant (Frisbee et al. 
2009). In this population, overall PFOA lev­
els were much higher [mean, 83.0 ng/mL; 
interquartile range (IQR), 13.4–70.6 ng/mL] 
than in corresponding U.S. population surveys 
(National Health and Nutrition Examination 
Survey in the same year: mean, 3.9 ng/mL; 
IQR, 2.7–5.8 ng/mL) (Frisbee et al. 2009; 
Kato et al. 2011). However, the mean PFOS 
(23.3 ng/mL; IQR, 13.8–29.0 ng/mL) 
closely resembled the U.S. population mean 
(20.7 ng/mL; IQR, 14.6–29.9 ng/mL) (Kato 
et al. 2011). The present study used these 
data to examine the cross­sectional association 
between serum PFOA or PFOS concentrations 
and markers of liver function in adults.
Methods
The study population. This study was approved 
by the London School of Hygiene and Tropical 
Medicine Ethics Committee and is one of the 
C8 Science Panel studies and used information 
from questionnaires and blood tests collected 
in the C8 Health Project, supplemented by 
further information on classification by water 
district developed in a companion C8 Science 
Panel study (Shin et al. 2011).
The C8 Health Project enrolled eligible 
subjects between August 2005 and August 
2006. Individuals were eligible to partici­
pate if they had consumed water for at least 
1 year between 1950 and 2004 while living, 
working, or going to school in one of the six 
water districts, or private water sources, or 
areas of documented PFOA contamina  tion. 
The between­ and within­group regression 
analysis was restricted to subjects living in one 
of the six contaminated water districts at the 
time of survey [for additional details on water 
districts, see Supplemental Material (http://
dx.doi.org/10.1289/ehp.1104436)]. Details 
of the study enrollment process, including 
consenting procedures, have been described 
elsewhere (Frisbee et al. 2009).
The C8 Health Project collected data on 
69,030 persons. Its participation rate, based 
on U.S. census numbers, has been estimated 
at around 80% (Frisbee et al. 2009). In this 
population, the strongest predictor of PFOA 
serum concentration was residence in one of the 
contaminated water districts (Steenland et al. 
2009), whereas serum levels of other PFAAs 
did not show such geographic variation. Of the 
population, 56,554 adults (≥ 18 years of age) 
were considered for this analysis, and a total of 
46,452 of those adults (82.1%) were included 
in the final analysis after exclusion of subjects 
with missing data on socioeconomic status, 
alcohol consumption, or cigarette smoking 
or other potential confounding variables or 
without PFAAs or liver enzymes measurements.
Choice of parameters and laboratory analy-
ses. Blood samples were obtained and processed 
at individual data collection sites. Samples were 
drawn into four tubes per participant, with a 
maximum of 35 mL blood collected. Samples 
were centrifuged, aliquoted, and refrigerated 
until shipping. Processed samples were shipped 
on dry ice daily from each data collection site to 
the laboratory (Frisbee et al. 2009). Participants 
were not asked to fast before blood sample 
withdrawal, but fasting status was recorded.
Laboratory analyses of PFAAs were con­
ducted by the Exygen Research Inc. (State 
College, PA, USA). using an automated solid­
phase extraction combined with reverse­phase 
high­performance liquid chromatography/
Table 1. Participant characteristics, Mid-Ohio Valley, 2005–2006.
Characteristic Women (n = 24,171) Men (n = 22,281) Total (n = 46,452) p-Valuea
Age (median/mean ± SD) 44.3/45.1 ± 15.9 45.5/45.8 ± 15.8 44.7/45.5 ± 15.9 < 0.001
Regular exercise [n (%)] 7,821 (32.4) 6,741 (30.3) 14,562 (31.4) < 0.001
BMI [n (%)]
Underweight 471 (2.0) 153 (0.7) 624 (1.3) < 0.001
Normal weight 8,236 (34.1) 5,156 (23.1) 13,392 (28.8)
Overweight 6,848 (28.3) 9,339 (41.9) 16,187 (34.9)
Obese, class I 4,545 (18.8) 5,066 (22.7) 9,611 (20.7)
Obese, class II 2,257 (9.3) 1,753 (7.9) 4,010 (8.6)
Obese, class III 1,814 (7.5) 814 (3.7) 2,628 (5.7)
Household income, US$/year [n (%)]
≤ 10,000 2,852 (11.8) 2,081 (9.3) 4,933 (10.6) < 0.001
10,001–20,000 4,127 (17.1) 3,018 (13.6) 7,145 (15.4)
20,001–30,000 3,899 (16.1) 3,636 (16.3) 7,535 (16.2)
30,001–40,000 3,340 (13.8) 3,265 (14.7) 6,605 (14.2)
40,001–50,000 2,690 (11.1) 2,664 (12.0) 5,354 (11.5)
50,001–60,000 2,207 (9.1) 2,277 (10.2) 4,484 (9.7)
60,001–70,000 1,736 (7.2) 1,817 (8.2) 3,553 (7.7)
> 70,000 3,320 (13.7) 3,523 (15.8) 6,843 (14.7)
Education [n (%)]
< 12 years 2,630 (10.9) 2,623 (11.8) 5,253 (11.3) < 0.001
High school diploma or GED 9,453 (39.1) 9,935 (44.6) 19,388 (41.7)
Some college 8,760 (36.2) 6,723 (30.2) 15,483 (33.3)
≥ Bachelor degree 3,328 (13.8) 3,000 (13.5) 6,328 (13.6)
Race [n (%)]
White 23,531 (97.4) 21,685 (97.3) 45,216 (97.3) 0.009
Black 209 (0.9) 245 (1.1) 454 (1.0)
Other 431 (1.8) 351 (1.6) 782 (1.7)
Alcohol consumption [n (%)]
None 13,487 (55.8) 9,968 (44.7) 23,455 (50.5) < 0.001
< 1 drink/month 5,251 (21.7) 3,128 (14.0) 8,379 (18.0)
< 1 drink/week 2,797 (11.6) 2,717 (12.2) 5,514 (11.9)
Few drinks/week 2,209 (9.1) 4,630 (20.8) 6,839 (14.7)
1–3 drinks/day 336 (1.4) 1,225 (5.5) 1,561 (3.4)
> 3 drinks/day 91 (0.4) 613 (2.8) 704 (1.5)
Smoking status [n (%)]
Never 12,775 (52.9) 9,489 (42.6) 22,264 (47.9) < 0.001
Former 5,178 (21.4) 6,998 (31.4) 12,176 (26.2)
Current < 10 cigarettes/day 2,836 (11.7) 1,900 (8.5) 4,736 (10.2)
Current 10–19 cigarettes/day 2,285 (9.5) 2,124 (9.5) 4,409 (9.5)
Current ≥ 20 cigarettes/day 1,097 (4.5) 1,770 (7.9) 2,867 (6.2)
ALT (IU/L)
Median/mean ± SD 17.0/20.8 ± 16.0 26/31.0 ± 22.5 21.0/25.7 ± 20.1 < 0.001
≤ 45 (m), ≤ 34 (w) [n (%)] 22,088 (91.4) 19,170 (86.0) 41,258 (88.8) < 0.001
> 45 (m), > 34 (w) [n (%)] 2,083 (8.6) 3,111 (14.0) 5,194 (11.2)
GGT (IU/L)
Median/mean ± SD 17.0/24.3 ± 31.0 27.0/37.5 ± 53.5 21.0/30.7 ± 43.7 < 0.001
≤ 55 (m), ≤ 38 (w) [n (%)] 21,243 (87.9) 19,219 (86.3) 40,462 (87.1) < 0.001
> 55 (m), > 38 (w) [n (%)] 2,928 (12.1) 3,062 (13.7) 5,990 (12.9)
Direct bilirubin (mg/dL)
Median/mean ± SD 0.1/0.1 ± 0.4 0.1/0.1 ± 0.6 0.1/0.1 ± 0.6 < 0.001
≤ 0.3 [n (%)] 24,045 (99.5) 21,901 (98.3) 45,946 (98.9) < 0.001
> 0.3 [n (%)] 126 (0.5) 380 (1.7) 506 (1.1)
PFOA, ng/mL [median (IQR)] 23.1 (11.3–58.2) 34.3 (16.6–85.1) 28.0 (13.5–70.8) < 0.001
PFOS, ng/mL [median (IQR)] 17.4 (11.6–25.5) 23.5 (16.8–32.6) 20.3 (13.7–29.4) < 0.001
Abbreviations: m, men; w, women.
ap-Value for chi-square test for categorical variables, and t-test for continuous variables–based testing the difference 
between sexes.Serum PFOA and PFOS and liver biomarkers
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mass spectrometry (Kuklenyik et al. 2004). An 
intralaboratory quality assurance program was 
carried out by analysis of duplicate samples 
at AXYS Analytical Service Ltd. (Sidney, BC, 
Canada) (Frisbee et al. 2009). The intralabora­
tory coefficient of variation for both PFOA 
and PFOS measurements was 0.1; the inter­
laboratory comparison coefficient of varia­
tion was 0.2 for PFOA and 0.1 for PFOS 
(Frisbee et al. 2009). The detection limit was 
0.5 ng/mL for both PFOA and PFOS, and 
observations below this limit were assigned a 
value of 0.25 ng/mL (for this study popula­
tion, n = 32 for PFOA, n = 230 for PFOS). 
Both PFOA and PFOS concentration distri­
butions were skewed to the right.
The liver parameters we measured were 
alanine aminostransferase (ALT) and aspartate 
aminostransferase (AST), GGT, alkaline phos­
phatase (ALP), and direct bilirubin (also known 
as “conjugated bilirubin”). Both transaminases 
(AST and ALT) are enzymes released after liver 
parenchymal cell injury and are elevated in 
serum during acute liver damage; the correla­
tion between ALT and AST in the present 
population is r = 0.79. To limit multiple com­
parisons and to be consistent with the most 
recent published literature on the same topic 
(Lin et al. 2010), we restricted our analysis to 
ALT, GGT, and direct bilirubin as markers 
of liver function. Elevated ALT has been used 
as a proxy for hepatocellular injury in previous 
studies (Clark et al. 2003; Ioannou et al. 2005; 
Lin et al. 2010; Ruhl and Everhart 2003) 
because it is more specific for hepatic damage 
than is AST. Elevation of GGT occurs at an 
early stage and is more persistent than that of 
ALP in cholestatic disorders (Whitfield 2001); 
the correlation between GGT and ALP in the 
present population was r = 0.29. Bilirubin is 
mostly derived from the metabolism of hemo­
globin; the increase in serum of the direct bili­
rubin component is highly specific for liver or 
bile duct disease (Sedlak and Snyder 2004). 
ALT, GGT, and direct bilirubin were 
measured using a Roche/Hitachi MODULAR 
automated analyzer (Roche Diagnostics, 
Indianapolis, IN, USA), and the analyses were 
performed at a large, independent, accredited 
clinical diagnostic laboratory (LabCorp, Inc., 
Burlington, NC, USA) (Frisbee et al. 2009). 
The homeostasis model assessment of insulin 
resistance (HOMA­IR) index was calculated as 
the product of basal glucose and insulin levels 
divided by 2.25; it is used as a surrogate measure 
for insulin resistance (Matthews et al. 1985).
Methods and results are described accord­
ing to the STrengthening the Reporting of 
OBservational studies in Epidemiology—
Molecular Epidemiology (STROBE­ME) 
guidelines (Gallo et al. 2011).
Statistical analysis. Distributions of con­
tinuous variables were inspected, and all 
three outcome markers were natural log (ln) 
transformed for linear regression models. We 
investigated univariate associations between 
exposure (serum concentration of PFOA 
and PFOS), liver function biomarkers (ALT, 
GGT, direct bilirubin), and potential con­
founders: age, physical activity, body mass 
index (BMI; classified as underweight/normal 
weight/overweight, obese class I/II/III), aver­
age household income (≤ $10,000, $10,001–
20,000, $20,001–30,000, $30,001–40,000, 
$40,001–50,000, $50,001–60,000, $60,001–
70,000, > $70,000), educational level [high 
school diploma or general educational devel­
opment (GED), some college, bachelor degree 
or higher], race (white, black, other), alcohol 
consumption (none, < 1 drink/month, < 1 
drink/week, few drinks/week, 1–3 drinks/day, 
> 3 drinks/day) and cigarette smoking (never 
smoker, former, current < 10 cigarettes/day, 
current 10–19 cigarettes/day, current ≥ 20 
cigarettes/day).
The association between ALT, GGT, 
or direct bilirubin and PFOA or PFOS was 
assessed using linear regression models. First, 
we fitted a simple model including only 
age and sex (model 1), followed by a model 
additionally including alcohol consumption, 
socioeconomic status, fasting status, race, and 
month of blood sample collection (model 2), 
and then a model additionally including 
smoking status, BMI, physical activity, and 
insulin resistance (i.e., HOMA­IR) in deciles 
of distribution (model 3).
Also, specific cutoff values were used to 
fit logistic regression models to estimate the 
impact of PFOA and PFOS on being above 
these values. Cutoff values used were 45 IU/L 
in men and 34 IU/L in women for ALT 
(Schumann et al. 2002a), giving a total of 
5,194 persons (11.2% of the 47,092 eligible 
participants) with above­normal values; 
55 IU/L in men and 38 IU/L in women 
for GGT (Schumann et al. 2002b), giving 
5,990 persons (12.9%) with above­normal 
values; and 0.3 mg/dL in men and women for 
direct bilirubin (Kratz et al. 2004), giving 506 
persons (1.1%) with above­normal values.
Prior research showed that individual 
serum levels of PFOA were strongly associated 
with the water district of residence (Steenland 
et al. 2009). This geographic clustering implies 
a potential for an ecological confounding by 
other uncontrolled and/or unobserved water 
district–specific factors. On the other hand, 
there is also potential for confounding at the 
individual level. We expect a priori some 
heterogeneity in between­ and within­group 
relationships; therefore, we applied an ana­
lytic approach in the multilevel framework 
[between­ and within­group regression (Davis 
et al. 1961)] to disentangle between­ and 
within­district effects of PFOA. In statisti­
cal modeling, this is realized by simultane­
ously incorporating both individual PFOA 
serum concentrations and the means of PFOA 
within water districts. Details of this analy­
sis are reported in the Supplemental Material 
(http://dx.doi.org/10.1289/ehp.1104436).
Results
General characteristics of the population are 
summarized in Table 1. Women had sig­
nificantly lower values of liver function bio­
markers and of PFOA and PFOS. PFOA and 
PFOS concentrations were associated with all 
potential confounders considered.
ln­Transformed values of ALT were signifi­
cantly associated with ln­PFOA and ln­PFOS in 
linear regression models [fully adjusted (model 
3) coefficient: PFOA, 0.022; 95% confidence 
interval (CI): 0.018, 0.025; PFOS, 0.020; 95% 
CI: 0.014, 0.026], with a partial R2 greater for 
the association with PFOA (partial R2 = 0.002) 
than for that with PFOS (partial R2 < 0.001; 
Table 2). In Figure 1, mean ALT levels are plot­
ted against deciles of PFOA and PFOS concen­
trations, adjusting for covariates by setting these 
to their means. A steady increase in fitted levels 
of ALT per decile of PFOA is shown, with a 
possible leveling off effect after approximately 
Table 2. Linear regression coefficients of ln-transformed blood analytes with a one-unit increase in 
ln-PFOA and ln-PFOS concentrations.
ln-PFOA  ln-PFOS
Liver function biomarker Coefficient (95% CI) R2 (partial R2)a  Coefficient (95% CI) R2 (partial R2)a
ln-ALT
Model 1b 0.018 (0.014, 0.021)** 0.170 (0.002) 0.029 (0.023, 0.036)** 0.170 (0.002)
Model 2c 0.014 (0.010, 0.018)** 0.174 (0.001) 0.026 (0.020, 0.033)** 0.175 (0.002)
Model 3d 0.022 (0.018, 0.025)** 0.265 (0.002) 0.020 (0.014, 0.026)** 0.263 (< 0.001)
ln-GGT
Model 1b 0.005 (–0.0001, 0.009) 0.145 (< 0.001) –0.008 (–0.016, –0.001) 0.145 (< 0.001)
Model 2c 0.004 (–0.001, 0.009) 0.166 (< 0.001) 0.006 (–0.002, 0.014) 0.166 (< 0.001)
Model 3d 0.015 (0.010, 0.019)** 0.249 (0.001) 0.008 (–0.0002, 0.016) 0.248 (< 0.001)
ln-Direct bilirubin
Model 1b 0.004 (0.001, 0.007)* 0.094 (< 0.001) 0.033 (0.028, 0.039)** 0.097 (0.003)
Model 2c 0.003 (0.0004, 0.006)* 0.121 (< 0.001) 0.034 (0.029, 0.040)** 0.124 (0.003)
Model 3d 0.001 (–0.002, 0.004) 0.163 (< 0.001) 0.029 (0.024, 0.034)** 0.166 (0.003)
aPartial R2, difference between R2 including and excluding PFOA or PFOS in the model. bAdjusted for age and sex. 
cAdjusted for alcohol consumption, socioeconomic status, fasting status, race, and month of blood sample collection in 
addition to adjustment in model 1. dAdjusted for smoking status, BMI, physical activity, and insulin resistance in addition 
to adjustment in model 2. *p < 0.05. **p < 0.001.Gallo et al.
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30 ng/mL. A comparable distribution is observ­
able for PFOS, although in a narrower range 
of exposure (Figure 1A,B). This positive asso­
ciation was also observed in logistic regression 
models with a steady increase in the odds ratio 
(OR) estimates across deciles of both PFOA 
and PFOS (p­value for trends across deciles in 
both models < 0.001), and a significant OR for 
both ln­unit of PFOA (OR = 1.10; 95% CI: 
1.07, 1.13) and ln­unit of PFOS (OR = 1.13; 
95% CI: 1.07, 1.18; Table 3). Subjects with 
abnormally high ALT values were evenly 
distributed across water districts (chi­square 
test, p = 0.172) and had significantly higher 
PFOA and PFOS serum concentrations 
compared with those with normal ALT val­
ues (PFOA: 106.8 vs. 84.6 IU/L, p < 0.001; 
PFOS: 24.3 vs. 23.3 IU/L, p < 0.001). No 
interaction between PFOA/PFOS deciles with 
fasting status was observed (p­values 0.816 and 
0.387,   respectively).
The association between ln­GGT and 
ln­PFOA reached a significant level in the fully 
adjusted model (model 3; coefficient, 0.015; 
95% CI: 0.010, 0.019) mainly due to the con­
tribution of insulin resistance and BMI, which 
appeared to be highly associated with ln­GGT 
(Table 2); fitted values of GGT by deciles of 
PFOA showed an apparent positive associa­
tion (Figure 1C), although it was less clear than 
that shown for ALT. The suggested association 
with PFOA, however, was not confirmed in 
the logistic regression model, in which no trend 
across deciles was observed (p = 0.213), or for 
the linear ln­units of PFOA values (OR = 1.01; 
95% CI: 0.99, 1.04; Table 3). For PFOS, there 
was some evidence of a slight inverse associa­
tion with GGT in the minimally adjusted lin­
ear regression model (model 1), which was 
lost after adjusting for additional confound­
ers (model 3; Table 2). The logistic regression 
by deciles of PFOS suggested a weak negative 
trend across deciles, although all ORs were close 
to 1, and no overall association with ln­PFOS 
was observed (Table 3). Overall, fitted values of 
GGT were unchanged across deciles of PFOS 
(Figure 1D). Subjects with abnormally high 
GGT values were more frequent in one district 
(chi­square test, p = 0.062) and had significantly 
higher PFOA serum concentrations (93.7 vs. 
86.1 IU/L, p = 0.004) but not PFOS serum 
concentrations (23.5 vs. 23.4 IU/L, p = 0.499).
For direct bilirubin, there was a suggestion 
of an inverse U­shaped relationship with PFOA, 
with increasing levels of bilirubin per increas­
ing levels of PFOA at low PFOA levels, and 
decreasing bilirubin levels for concentrations 
of PFOA above about 40 ng/mL (Figure 1E). 
Overall, the linear regression relationship failed 
Figure 1. Fitted values of ALT (A,B), GGT (C,D), and direct bilirubin (E,F) levels (mean and 95% CI, from fully 
adjusted regression model) by deciles of PFOA (A,C,E) and PFOS (B,D,F) concentrations, given the mean 
values of the other covariates. Graph pairs are on the same scale.
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Table 3. Logistic regression ORa (95% CI) of having abnormal high values of ALT, GGT, or direct bilirubin across deciles of PFOA and PFOS.
Decile ALT GGT Direct bilirubin Decile ALT GGT Direct bilirubin
PFOA PFOS
Decile 1 Reference Reference Reference Decile 1 Reference  Reference  Reference
Decile 2 1.09 (0.94, 1.26) 1.06 (0.93, 1.21) 1.01 (0.66, 1.54) Decile 2 1.01 (0.87, 1.16) 1.06 (0.94, 1.20) 0.75 (0.47, 1.20)
Decile 3 1.19 (1.03, 1.37) 1.07 (0.94, 1.21) 1.04 (0.69, 1.56) Decile 3 1.06 (0.91, 1.22) 0.95 (0.83, 1.07) 0.62 (0.39, 1.01)
Decile 4 1.26 (1.09, 1.45) 1.05 (0.93, 1.20) 0.95 (0.62, 1.44) Decile 4 1.11 (0.96, 1.28) 0.93 (0.82, 1.06) 0.72 (0.46, 1.13)
Decile 5 1.40 (1.22, 1.62) 1.11 (0.97, 1.26) 0.89 (0.58, 1.37) Decile 5 1.19 (1.04, 1.37) 0.96 (0.84, 1.09) 0.85 (0.55, 1.31)
Decile 6 1.39 (1.21, 1.60) 1.10 (0.96, 1.25) 1.03 (0.68, 1.56) Decile 6 1.19 (1.04, 1.37) 1.03 (0.91, 1.17) 0.95 (0.63, 1.44)
Decile 7 1.31 (1.14, 1.52) 1.20 (1.06, 1.37) 0.86 (0.56, 1.32) Decile 7 1.20 (1.04, 1.38) 0.97 (0.85, 1.10) 1.01 (0.67, 1.52)
Decile 8 1.42 (1.23, 1.64) 1.13 (0.99, 1.29) 0.95 (0.62, 1.45) Decile 8 1.24 (1.08, 1.43) 0.91 (0.80, 1.04) 0.93 (0.61, 1.41)
Decile 9 1.40 (1.21, 1.62) 1.06 (0.93, 1.22) 0.80 (0.52, 1.25) Decile 9 1.18 (1.02, 1.36) 0.89 (0.78, 1.01) 0.91 (0.60, 1.39)
Decile 10 1.54 (1.33, 1.78) 1.06 (0.92, 1.20) 1.01 (0.66, 1.53) Decile 10 1.25 (1.08, 1.44) 0.94 (0.83, 1.07) 1.23 (0.82, 1.83)
Trendb  < 0.001 0.213 0.496 Trendb  < 0.001 0.047 0.015
ln-Unitc 1.10 (1.07, 1.13) 1.01 (0.99, 1.04) 0.97 (0.90, 1.05) ln-unitc 1.13 (1.07, 1.18) 0.98 (0.94, 1.02) 1.11 (0.96, 1.28)
p-Valuec < 0.001 0.298 0.512 p-Valuec < 0.001 0.310 0.168
aAdjusted by age, sex, alcohol consumption, socioeconomic status, fasting status, month of blood sample collection, smoking, BMI, physical activity, increased serum iron, and insulin 
resistance. bp-Value for trend across deciles. cOR and relative 95% CI and p-value for ln-PFOA/PFOS.Serum PFOA and PFOS and liver biomarkers
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to show any association in the adjusted model 
(Table 2), and the likelihood ratio test after 
introducing the quadratic term was statistically 
significant (p < 0.001). In accordance, no pat­
tern was evident in the logistic regression mod­
els of high bilirubin (Table 3). By contrast, for 
PFOS, a clear positive association was shown 
in linear regression models for direct biliru­
bin (coefficient, 0.029; 95% CI: 0.024, 0.034; 
Table 2, Figure 1F), although this was not evi­
dent in logistic regression models (Table 3). 
However, logistic regression results for direct 
bilirubin should be interpreted cautiously 
because only 1.1% of the whole sample had 
high levels and CIs were wide.
Multilevel analysis was restricted to subjects 
living in water districts supplied by contami­
nated water (n = 26,777) and excluding those 
with private wells. The fitted values for each of 
the outcomes of ALT, GGT, and direct bili­
rubin versus mean PFOA serum level for the 
six water districts are graphed in Figure 2. In 
Table 4, the regression coefficients per ln­unit 
of PFOA for a model between water districts 
comparing district averages of ln­PFOA (B) 
and for a model within water districts com­
paring differences from the average (W) are 
presented. There was a significant difference 
between the between­ and within­district com­
ponents (p­value B/WΔ) for ALT and direct 
bilirubin; however, each outcome showed dif­
ferent patterns. The between­  water­district 
regression coefficient from linear regression of 
ln­PFOA and ALT (0.010; 95% CI: –0.001, 
0.020) was lower than the within­water­district 
coefficient (0.027; 95% CI: 0.022, 0.031). 
However, both coefficients were significant 
or borderline significant, in the same direc­
tion, and consistent with a positive associa­
tion between ALT and PFOA levels. Although 
the regression coefficient for the association 
between GGT and ln­PFOA within water dis­
trict was positive and significant (0.016; 95% 
CI: 0.010, 0.023), this association was not sig­
nificant in the between­water­district analysis 
(0.005; 95% CI: –0.009, 0.018); the p­value 
for interaction between/within water district 
was not significant (p = 0.108). Conversely, 
there was a significant inverse relationship 
between ln­PFOA and direct bilirubin between 
water districts (–0.013; 95% CI: –0.022, 
–0.005) but not within water districts (0.0001; 
95% CI: –0.004, 0.004).
Discussion
These results show a positive association 
between PFOA and PFOS concentrations and 
ALT serum levels, a marker of hepatocellular 
damage. The linear association, consistently 
replicated in all analyses, showed a monotonic 
increase in logistic regression. Furthermore, the 
presence of a consistent relationship in regres­
sion analysis both between water districts and 
among individuals within districts increases 
strength of evidence for causal association. The 
proportion of laboratory abnormal values rises 
in relation to PFOA, but the small amount 
of variation in outcomes explained by PFOA 
(partial R2 ≤ 0.1%) suggests caution.
The observed associations between PFOA 
or PFOS and ALT are generally consistent in 
terms of direction and magnitude with previ­
ous findings of occupational studies. A cross­
sectional study of 1,025 workers at the same 
plant leading to the C8 Health Project reported 
an association between PFOA and ALT levels 
with a similar coefficient (mean ± SE coeffi­
cient of log­transformed values, 0.023 ± 0.015; 
p = 0.124). A significant linear regression coef­
ficient between log­transformed–PFOA and 
log­ALT (coefficient, 0.025 ± 0.013; p = 0.006) 
was described in a cross­sectional occupational 
surveillance conducted in three 3M plants in 
the United States and Belgium (Olsen and 
Zobel 2007). A small occupational study con­
ducted in Italy showed a significant positive 
association between PFOA and ALT levels 
among workers exposed to PFOA (coefficient, 
0.116; 95% CI: 0.054, 0.177; p < 0.01) (Costa 
et al. 2009). Notably, these results are also 
consistent with data coming from a general 
population survey (mean ± SE linear regression 
coefficients with ALT: PFOA, 1.86 ± 0.62, 
p = 0.005; PFOS, 1.01 ± 0.53, p = 0.066) 
where background concentrations of PFOA are 
much lower than those reported here (Lin et al. 
2010). Only one previous study of this same 
population reported no association with ALT 
(regression coefficient = –0.00416, p = 0.65); 
however, the observation was based on a much 
smaller sample (most of whom were likely to 
be included in the present analysis) and based 
on figures coming from models including non­
log­transformed exposure or outcome variables 
(Emmett et al. 2006).
Evidence for an association between PFOA 
and PFOS and GGT is not so clear. Although 
there was some suggestion of an association 
in the linear regression models with PFOA, it 
was not replicated in logistic regression models. 
The instability of linear regression coefficients 
(which are very sensitive to the inclusion of 
additional covariates) might be due to a con­
founding effect of diet, or residual confound­
ing of alcohol consumption, which causes a 
direct increase of GGT. Finally, the absence of 
any trend across districts—even though there 
are large contrasts in between­district mean 
exposures—might be indicative of some con­
founding factor acting at the individual level. 
As shown recently, GGT levels are positively 
associated with alcohol and meat intake after 
adjusting for all potential non  dietary confound­
ers (Lee et al. 2004). To support this, there is 
indirect evidence from an occupational study 
that reported a significant association between 
ln­GGT and ln­PFOA in models adjusted by 
ln­age, ln­BMI, and ln­alcohol (mean ± SE coef­
ficient, 0.033 ± 0.017, p = 0.05), which drops if 
Figure 2. Fitted values of ALT (A), GGT (B), and direct bilirubin (C) levels (mean and 95% CI; from fully adjusted regression model) by mean PFOA concentration in 
the water district, given the mean values of the other covariates. 
51 02 04 08 0 160 320 640 51 02 04 08 0 160 320 640 51 02 04 08 0 160 320 640
PFOA concentration (ng/mL) PFOA concentration (ng/mL) PFOA concentration (ng/mL) 
24
23
22
21
20
26
25
24
23
22
21
0.112
0.110
0.108
0.106
0.104
A
L
T
 
(
I
U
/
L
)
G
G
T
 
(
I
U
/
L
)
D
i
r
e
c
t
 
b
i
l
i
r
u
b
i
n
 
(
m
g
/
d
L
)
Table 4. Multilevel analysis of PFOA between and within district effects.
Liver function biomarker
Coefficient between districts 
(95% CI)
Coefficient within districts 
(95% CI) p-Valuea
ln-PFOA
ALT 0.010 (–0.001, 0.020)# 0.027 (0.022, 0.031)** 0.003
GGT 0.005 (–0.009, 0.018) 0.016 (0.010, 0.023)** 0.108
Direct bilirubin –0.013 (–0.022, –005)* 0.0001 (–0.004, 0.004) 0.004
ap-Value testing the null hypothesis of no difference between and within water district. *p < 0.05. **p < 0.001. #p = 0.062.Gallo et al.
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BMI is replaced by ln­tryglicerides (a proxy for 
diet) in the model (coefficient, 0.010 ± 0.016, 
p = 0.55) (Olsen and Zobel 2007).
PFOA concentration has a positive asso­
ciation with direct bilirubin up to 40 ng/mL, 
followed by a decrease of bilirubin levels after 
this peak. A negative association between 
PFOA or PFOS and direct bilirubin has been 
observed in some occupational studies (Costa 
et al. 2009; Olsen and Zobel 2007; Sakr 
et al. 2007b), which might be because they 
used mainly subjects in the higher range of 
exposure, missing the first part of an inverse 
U­shaped curve. The figures of the between­
district comparison might reflect the fact that 
the means of the four highest districts are well 
above the value of 30 ng/mL and may account 
for a larger portion of the observed association 
above that value, or this may be evidence of 
some geographic confounding.
The hepatotoxic effect of PFOA in rodents 
leading to liver enlargement and altered hepato­
cyte histology (Qazi et al. 2010) appears to be 
mediated in part by PPAR­α agonism, lead­
ing to altered expression of the genes involved 
in peroxisome proliferation, cell cycle control, 
and apoptosis (Lau et al. 2007). Although dif­
ferent mechanisms also play a role in humans 
(Bjork et al. 2011), human cellular responses do 
predict a PPAR­α response (Rakhshandehroo 
et al. 2009; Yang et al. 2008). In the human 
population data presented here, the association 
of PFOS concentration with increasing trans­
aminase is almost as prominent as the associa­
tion for PFOA, and human laboratory cell data 
indicate relatively lower response of liver cells to 
PFOS than to PFOA (Wolf et al. 2008).
The consistency and significance of asso­
ciations of ALT end points outside the normal 
range with PFOA serum concentration suggest 
a true association with an underlying hepato­
toxic effect in humans. However, only a small 
proportion of end points fell outside the normal 
value range, making the observed results more 
difficult to interpret in terms of human health 
risk. In particular, it is not clear if this small 
increase in ALT levels can lead to clinically diag­
nosable conditions in the future, or if this effect 
is reversible (i.e., if it is reduced after removal of 
the exposure to PFOA). Finally, results coming 
from this study need to be read in the context 
of health effect of PFAAs on humans, but data 
cannot be directly used for estimating single­
subject damage in relation to exposure.
The main limitation of the present study is 
the cross­sectional design, which makes causal 
inference particularly difficult. However, 
the consistency of the findings with previ­
ous literature—in particular the association 
with ALT—reinforces the hypothesis of a true 
association. Also, self­reported data of lifestyle 
characteristics being strongly associated with 
the exposures of interest can hamper a correct 
adjustment for potential confounders, which 
might be of particular relevance given the 
small magnitude of the observed associations. 
However, this study is the largest reported 
so far on this topic on a population­based 
sample of residents exposed to relatively high 
concentrations of PFOA.
Conclusions
A small but clear linear association between 
PFOA and PFOS serum concentrations and 
ALT, a marker of hepatocellular injury, was 
observed in this large population­based sam­
ple of individuals with exposure to PFAAs. 
These results are consistent with previous 
findings and warrant further investigation, 
in particular on the potential health conse­
quence of long­term exposure and potential 
  accumulation of damage.
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